[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The HIV Netherlands Australia Thailand Research Collaboration\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100088575","a-long-term-follow-up-of-the-hiv-nat-cohort-100088575",false,"NCT00411983","A Long-term Follow-up of the HIV-NAT Cohort","A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols","Inclusion Criteria:\n\n* HIV infected patients( children and adults) previously participated HIV-NAT studies\n* HIV infected patients( children and adults) currently participate in HIV-NAT trials\n* Able to provide written consent\n\nExclusion Criteria:\n\n* Unable to provide written consent","ALL","18 Years",{"count":19,"type":20},10000,"ESTIMATED","OBSERVATIONAL","With HIV\u002FAIDS increasingly considered a chronic disease, 24-, or 48-week data from antiretroviral studies are no longer sufficient. Only with long-term follow-up and outcome data will shed some much-needed light on the answers of questions that have stumped us for several years. Data from a large observational cohort of patients treated with combination antiretroviral therapy will provide further insights into the long-term safety and durability of various antiretroviral therapeutic approached, the efficacy of HIV viral load and CD4 cell counts as predictors of disease progression and mortality, and the importance of adherence.",[24],"HIV Infections",[26,27],"chronic HIV infection","long term cohort of HIV infection","RECRUITING","2025-03-14",{"date":31,"type":32},"2025-03-17","ACTUAL",{"date":34,"type":32},"2002-11",{"date":36,"type":20},"2030-12",{"name":38,"class":39},"The HIV Netherlands Australia Thailand Research Collaboration","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100466218","thailand-hdv-cohort-100466218","NCT05350865","Thailand HDV Cohort","Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024","Inclusion Criteria:\n\n1. Male or female, aged 18 years and older\n2. Chronically-infected with HBV, as defined by:\n\n   Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result\n3. Provide signed and dated informed consent form.\n\nExclusion Criteria:\n\nNon chronic HBV",{"count":49,"type":20},3152,"There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells\u002Fcount, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV\u002FHIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment",[52],"HDV",[54,52,55,56],"HBV","cirrhosis","Thailand","2024-09-30",{"date":59,"type":32},"2024-10-02",{"date":61,"type":32},"2023-01-30",{"date":63,"type":20},"2025-05",{"name":38,"class":39},4,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100341897","phase-2-efficacy-safety-and-pharmacokinetics-of-dtg-with-rif-100341897","NCT03731559","Efficacy, Safety and Pharmacokinetics of DTG with RIF","Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 Mg Once Daily with Food Versus Dolutegravir 50 Mg Twice Daily in HIV\u002FTB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy","Inclusion Criteria:\n\n1. documented HIV positive\n2. Aged \\>18 years\n3. ARV naïve (previous exposure to ARV for \\\u003C 2 weeks)\n4. Any CD4 cell count\n5. ALT \\\u003C5 times ULN\n6. estimated GFR\\>60 ml\u002Fmin\u002F1.73m2\n7. Hemoglobin \\>7 mg\u002FL\n8. TB is diagnosed and there is a plan to receive stable doses of RIF containing anti-TB therapy for at least another 4 week period after initiation of ART\n9. No other active OI (CDC class C event) except oral candidiasis or disseminated MAC\n10. Body weight \\>40kg\n11. Able to provide written informed consent\n\nExclusion Criteria:\n\n1. Have documented history of HIV treatment failure or HIV mutation to NRTI, NNRTI, and\u002For INIs\n2. Have previously treated for tuberculosis\n3. Currently using immunosuppressive agents.\n4. Currently using any prohibited medications that can affect the pharmacokinetics of the study drug such as phenobarbital, and carbamazepine\n5. Currently using alcohol or illicit substances that may affect the conduct of the trial as per the opinion of the site Principal Investigator\n6. Unlikely to be able to remain in the follow-up period as defined by the protocol\n7. Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST \\\u003C 5 x ULN.\n8. Have Karnofsky performance score \\\u003C30%\n9. Have TB meningitis, bone\u002Fjoints (due to prolonged use of anti-TB drug)\n10. Pregnant or breastfeeding",{"count":74,"type":20},200,"INTERVENTIONAL",[77],"PHASE2","The overall aim of the project is to evaluate optimal DTG dose for the combined treatment of TB and HIV infections with RIF based anti-TB therapy. This Stage II trial will determine precisely the PK parameters of DTG in combination with RIF regimen in Thai HIV\u002FTB co-infected patients. After the optimal dose of DTG has been found, it will be further tested in a larger Stage III trial to assess its safety, tolerability and efficacy when used with RIF based regimen.",[80],"HIV\u002FTB Coinfection",[82,83,84,85,86,87],"Efficacy","safety","pharmacokinetics","Dolutegravir","HIV\u002FTB co-infected patients","rifampin-based antituberculosis therapy",{"date":59,"type":32},{"date":90,"type":32},"2019-06-25",{"date":92,"type":20},"2025-06-30",{"name":38,"class":39},10,""]